Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels.
|
14563827 |
2003 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The Ala54Thr polymorphism in the fatty acid-binding protein 2 (FABP2) gene as well as the T-455C and C-482T polymorphisms in the apolipoprotein C-III (APOC3) gene promoter have been associated with features of the MS in specific populations.
|
15598690 |
2005 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
AGT T174M, GNB3 825C>T, and APOC3 -455T>C genotypes were significantly associated with MetS (P = 0.018, 0.0056, and 0.029, respectively) for female adults, whereas FABP2 A54T genotype was associated with MetS (P = 0.040) for female adolescents.
|
15869758 |
2006 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
RGD |
Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population.
|
16298371 |
2006 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the influence of cholesterol ester transfer protein (CETP) TaqIB polymorphism, lipoprotein lipase (LPL) PvuII and HindIII polymorphisms, hepatic lipase (LIPC) G-250A polymorphism and apolipoprotein C-III (APOC3) SstI gene polymorphism on lipid levels in dyslipidemia of the metabolic syndrome, 150 patients with dyslipidemia of metabolic syndrome were included.96 % of patients had type 2 diabetes.
|
16343038 |
2006 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These data, therefore, suggest that the APOC3 promoter polymorphisms C-482T and T-455C are associated with the MetS.
|
17416293 |
2007 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Carriers of > or =1 copy of APOC3 -455C were more likely to have MetS (NCEP ATP III definition) than noncarriers (carrier odds ratio 1.73, 95% CI 1.40 to 2.14, adjusting for age and study group).
|
18096054 |
2007 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
ApoE epsilon2/epsilon3/epsilon4 gene polymorphism is a determinant of the relative proportion of apolipoprotein C-III to E. Carriers of the unfavourable E4 allele present the highest ApoCIII/ApoE ratio and are twofold more frequent among individuals affected by MetSyn.
|
18188530 |
2007 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
LHGDN |
This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the metabolic syndrome.
|
18509206 |
2008 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
There was no association between the APOC3 -482C>T or APOC3 3238C>G polymorphisms and metabolic syndrome.
|
18789138 |
2008 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A5 gene (APOA5) variants are associated with increased plasma triglycerides, a risk factor for the metabolic syndrome (MS), but a correlation with apolipoprotein C3 (APOC3) genotypes is controversial.
|
19932084 |
2010 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Single-nucleotide polymorphisms in the genes encoding for IL-6 (g.-634G>C; c.174G>C), TNFα (g.-308G>A), methylenetetrahydrofolate reductase (MTHFR) (c.677C>T), APOC3 (c.3175C>G), and APOA5 (g.-1131T>C) have been implicated in the processes of inflammation and energy intake that take place in the development of MetS manifestations.
|
21473680 |
2011 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.
|
21749608 |
2011 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus.
|
23542898 |
2013 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In the joint analysis, the associations of the WDP and APOC3 rs5128 with MetS risk tended to be dependent on APOC3 3238C>G gene variants (p for interaction = 0.009) in women.
|
25301527 |
2014 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Compared with other genotype combinations, the combined effect of APOC3/APOA1 (CC/GA+AA/CT+TT) genotypes showed a further increase in the risk of the MetS in the highest quartile of WDP scores (OR 1, 2·49, 8·73, 6·32, P trend< 0·001, P(interaction)= 0·003).
|
25653052 |
2015 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.
|
26824674 |
2016 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The rs5128 (APOC3) and rs340874 (PROX1) polymorphisms were found to be significantly associated with susceptibility to MetS (P=0.003 and P=0.033, respectively), with odds ratios (ORs) of 4.39 (95% CI=1.66-11.56) and 2.81 (95% CI=1.09-7.27), respectively.
|
28919193 |
2017 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The western DP had a significant interaction with APOC3, APOA1 and MC4R polymorphisms in relation to MetS.
|
30584439 |
2018 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
ApoC3 is a promising therapeutic target for hypertriglyceridemia in patients with MetS and diabetes.
|
30723097 |
2019 |